Adipose-Derived SVF Cells for Transplant Vascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for tissue, organ, and cell transplantation face challenges in achieving rapid vascularization, particularly in the absence of pre-existing vessels, limiting the amount of tissue that can be transplanted and hindering integration into the host environment.
Innovation Solution
The use of stromal vascular fraction (SVF) cells, derived from adipose tissue, is introduced to enhance vascularization by mixing them with a gel or encapsulating transplanted tissues, promoting the formation of neovessels and accelerating blood flow restoration at the transplant-host interface without the need for pre-growth of a microvascular bed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cultured human endothelial cells are used to build a vascular system for tissue engineered constructs, then vascularization is achieved, but the process becomes labor intensive and time-consuming
Solution Approach 1:
The patent extracts the vascular-forming capability from cultured endothelial cells and transfers it to adipose-derived stem cells, which can form vessels more rapidly without requiring extensive pre-culturing. This extraction of the essential vascularization function enables faster integration.
Solution Approach 2:
The patent changes the cell type parameter from cultured human endothelial cells to adipose-derived stem cells, and modifies the timing parameter by eliminating the requirement for pre-growth of a microvascular bed. This allows vascularization to occur naturally after transplantation rather than requiring weeks of prior culturing.
2Productivity
If the transplant lacks pre-existing vessels capable of inosculation, then the transplant can be immediately implanted, but the amount of tissue that can be transplanted is limited by oxygen diffusion
Solution Approach 1:
The patent performs preliminary action by injecting adipose-derived stem cells into the transplant before implantation. These cells prepare the tissue by establishing a framework that will rapidly support vascular ingrowth, enabling larger tissue volumes to be transplanted successfully.
Solution Approach 2:
The adipose-derived stem cells act as an intermediary between the transplanted tissue and the host vasculature. They create a transitional environment that facilitates rapid vascular ingrowth and inosculation, bridging the gap that would otherwise limit tissue size.
3Quantity of substance
If larger amounts of tissue are transplanted, then more tissue can be restored, but sufficient blood supply to constituent cells becomes difficult to ensure
Solution Approach 1:
The patent performs preliminary action by pre-loading the transplant with adipose-derived stem cells that will rapidly differentiate and form vascular networks. This preliminary preparation ensures that even large tissue volumes receive adequate blood supply from the outset.
Solution Approach 2:
The patent applies local quality by concentrating adipose-derived stem cells at the transplant-host interface and within the tissue matrix. This localized cell placement creates zones of rapid vascularization that ensure adequate blood supply throughout the entire transplanted tissue volume.
Data Source
Figure 1~2D
Figure 3A~3F
Figure 4~5
AI summary
The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. Another aspect provides a composition comprising an engineered corpus cavernosum tissue comprising SVF cells and corpus cavernosum cells, wherein the SVF cells can be mixed with or encasing the corpus cavernosum cells, and methods of uses thereof, for example in method for the treatment of impotence and erectile dysfunction and/or enhance or contruct a penis. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.